替格瑞洛用于经皮冠状动脉介入术治疗急性冠状动脉综合征患者的价值及对术后不良心脏事件与血脂和血小板聚集功能的影响  

The value of ticagrelor for percutaneous coronary intervention in patients with acute coronary syndrome and its effect on postoperative adverse cardiac events,blood lipids and platelet aggregation

作　　者：李云峰 胡荣鑫 聂恒浩[1] LI Yunfeng;HU Rongxin;NIE Henghao(Department of Cardiovascular Division,Shenyang Second Hospital of Traditional Chinese Medicine,Shenyang,Liaoning,110101,China)

机构地区：[1]沈阳市第二中医医院心内科,辽宁沈阳110101

出　　处：《当代医学》2022年第18期107-110,共4页Contemporary Medicine

摘　　要：目的 探讨替格瑞洛用于经皮冠状动脉介入术(PCI)治疗急性冠状动脉综合征(ACS)患者的价值及对术后不良心脏事件与血脂和血小板聚集功能的影响。方法 选取2019年1月至2021年1月于本院行PCI治疗的106例ACS患者作为研究对象,按双色球法分为对照组和观察组,每组53例。对照组采用阿司匹林+氯吡格雷方案治疗,观察组采用替格瑞洛+阿司匹林方案治疗,比较两组血脂、血小板聚集功能及不良心脏事件发生情况。结果 治疗前,两组总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)水平比较差异无统计学意义;治疗后,两组HDL-C水平比较差异无统计学意义,观察组TG、TC和LDL-C水平均低于对照组,差异有统计学意义(P<0.05)。治疗前,两组血小板最大聚集率(MPAR)、P2Y12反应单位(PRU)水平比较差异无统计学意义;治疗后,观察组MPAR、PRU水平均低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组不良心脏事件发生率为5.66%,低于对照组的20.75%,差异有统计学意义(P<0.05)。结论 PCI治疗ACS前应用替格瑞洛可以降低患者血脂水平,提高抗血小板聚集功能,安全性较高,值得临床应用。Objective To investigate the value of ticagrelor for percutaneous coronary intervention(PCI) in patients with acute coronary syndrome(ACS) and its effect on postoperative adverse cardiac events and blood lipid and platelet aggregation.Methods 106 ACS patients who underwent PCI in our hospital from January 2019 to January 2021 were selected as the research subjects,and they were divided into the control group and the observation group according to the two-color ball method,with 53 cases in each group.The control group was treated with aspirin+clopidogrel,and the observation group was treated with ticagrelor+aspirin,and the blood lipids,platelet aggregation function and the occurrence of adverse cardiac events were compared between the two groups.Results Before treatment,there was no significant difference in the levels of total cholesterol(TC),triacylglycerol(TG),low density lipoprotein cholesterol(LDL-C) and high density lipoprotein cholesterol(HDL-C) between the two groups;after treatment,there was no significant difference in the levels of HDL-C between the two groups,and the levels of TG,TC and LDL-C in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in the maximum platelet aggregation rate(MPAR) and P2Y12response unit(PRU) levels between the two groups;after treatment,the levels of MPAR and PRU in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).After treatment,the incidence of adverse cardiac events in the observation group was 5.66%,which was lower than 20.75% in the control group,and the difference was statistically significant(P<0.05).Conclusion The application of ticagrelor before PCI in the treatment of ACS can reduce blood lipid levels and improve the anti-platelet aggregation function,with high safety and worthy of clinical application.

关 键 词：急性冠状动脉综合征 经皮冠状动脉介入术 替格瑞洛 氯吡格雷 不良心脏事件 

分 类 号：R541.4[医药卫生—心血管疾病]